Try a new search

Format these results:

Searched for:



Total Results:


Patient-Friendly Summary of the ACR Appropriateness Criteria®: Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2023 Update

Newman, Rachael; Heller, Samantha L
PMID: 37871635
ISSN: 1558-349x
CID: 5628122

Breast Imaging Essentials

Gao, Yiming; Heller, Samantha L.
ISSN: 0033-8389
CID: 5629332

21st-Century Breast Imaging: Improving Sensitivity and Specificity The 2023 RadioGraphics Monograph Issue [Editorial]

Giess, Catherine S; Heller, Samantha L
PMID: 37792589
ISSN: 1527-1323
CID: 5609532

Update on Lobular Neoplasia

Heller, Samantha L; Gao, Yiming
Lobular neoplasia (LN) is a histopathologic entity that encompasses both lobular carcinoma in situ (LCIS) and atypical lobular hyperplasia (ALH). Management of LN is known to be variable and institutionally dependent. The variability in approach after a diagnosis of LN at percutaneous breast biopsy derives in part from heterogeneity in the literature, resulting in a range of reported upgrade rates to malignancy after initial identification at percutaneous biopsy, and also from historical shifts in understanding of the natural history of LN. It has become increasingly recognized that not all LN is the same and that distinct variants of LN such as pleomorphic LCIS and florid LCIS have distinct natural histories and distinct likelihoods of upgrade to malignancy. In addition, it is also increasingly understood that appropriate management of LN relies on scrupulous radiologic-pathologic correlation. This review details the imaging features and histopathologic nature of ALH, classic-type LCIS, and the LCIS variants; addresses changes in the historical understanding of this entity contributing to confusion regarding its management; and discusses the importance of performing radiologic-pathologic correlation after percutaneous biopsy to help guide appropriate management steps when LN is encountered. In addition to the short-term implications of an LN diagnosis in terms of upgrade and surgical outcomes, the long-term implications of an LN diagnosis regarding risk of developing a later breast cancer are examined. ©RSNA, 2023 Quiz questions for this article are available through the Online Learning Center.
PMID: 37676825
ISSN: 1527-1323
CID: 5598822

Patient-Friendly Summary of the ACR Appropriateness Criteria Postmenopausal Subacute or Chronic Pelvic Pain

Donnelly, Lauren; Heller, Samantha L
PMID: 35750627
ISSN: 1558-349x
CID: 5282352

Patient-Friendly Summary of the ACR Appropriateness Criteria®: Seizures and Epilepsy

Newman, Rachael; Heller, Samantha L
PMID: 37495033
ISSN: 1558-349x
CID: 5628042

PACS-integrated machine learning breast density classifier: clinical validation

Lewin, John; Schoenherr, Sven; Seebass, Martin; Lin, MingDe; Philpotts, Liane; Etesami, Maryam; Butler, Reni; Durand, Melissa; Heller, Samantha; Heacock, Laura; Moy, Linda; Tocino, Irena; Westerhoff, Malte
OBJECTIVE:To test the performance of a novel machine learning-based breast density tool. The tool utilizes a convolutional neural network to predict the BI-RADS based density assessment of a study. The clinical density assessments of 33,000 mammographic examinations (164,000 images) from one academic medical center (Site A) were used for training. MATERIALS AND METHODS/METHODS:This was an IRB approved HIPAA compliant study performed at two academic medical centers. The validation data set was composed of 500 studies from one site (Site A) and 700 from another (Site B). At Site A, each study was assessed by three breast radiologists and the majority (consensus) assessment was used as truth. At Site B, if the tool agreed with the clinical reading, then it was considered to have correctly predicted the clinical reading. In cases where the tool and the clinical reading disagreed, then the study was evaluated by three radiologists and the consensus reading was used as the clinical reading. RESULTS:For the classification into the four categories of the Breast Imaging Reporting and Data System (BI-RADS®), the AI classifier had an accuracy of 84.6% at Site A and 89.7% at Site B. For binary classification (dense vs. non-dense), the AI classifier had an accuracy of 94.4% at Site A and 97.4% at Site B. In no case did the classifier disagree with the consensus reading by more than one category. CONCLUSIONS:The automated breast density tool showed high agreement with radiologists' assessments of breast density.
PMID: 37421715
ISSN: 1873-4499
CID: 5539562

Breast Cancer Screening Utilization and Outcomes in Women With Neurofibromatosis Type 1

Yan, Kevin; Gao, Yiming; Heller, Samantha L
INTRODUCTION:Women with neurofibromatosis type 1 (NF1) have up to a 5-fold increased risk for breast cancer before age 50 and a 3.5-fold increased risk of breast cancer overall. The purpose of our study was to assess breast cancer screening utilization and outcomes in this population. PATIENTS AND METHODS:This IRB approved HIPAA compliant study retrospectively assessed consecutive NF1 patients (January 2012-December 2021) with recorded clinical visits and/or breast imaging. Patient demographics, risk factors, and screening mammogram and breast magnetic resonance imaging (MRI) outcomes were recorded. Descriptive statistics were obtained and standard breast screening measures were calculated. RESULTS:One hundred and eleven women (median age 43, range 30-82) were eligible for screening based on current NCCN guidelines. A total of 86% (95/111) of all patients and 80% (24/30) of patients under age 40 had at least 1 mammogram. In contrast, 28% (31/111) of all patients and 33% (25/76) of patients ages 30 to 50 had at least 1 screening MRI. Of 368 screening mammograms performed, 38 of 368 (10%) resulted in the recall, and 22 of 368 (6%) resulted in a biopsy. Of 48 screening MRIs performed, 19 of 48 (40%) short-term follow-ups and 12 of 48 (25%) biopsies were recommended. All 6 screen-detected cancers in our cohort were detected initially on screening mammograms. CONCLUSION:Results confirm the utility and performance of screening mammography in the NF1 population. The low utilization of MRI in our cohort limits the evaluation of outcomes via this modality and suggests there may be an education or interest gap among referrers and patients regarding supplemental screening recommendations.
PMID: 36863889
ISSN: 1938-0666
CID: 5540762

Women 75 Years Old or Older: To Screen or Not to Screen?

Lee, Cindy S; Lewin, Alana; Reig, Beatriu; Heacock, Laura; Gao, Yiming; Heller, Samantha; Moy, Linda
Breast cancer is the most common cancer in women, with the incidence rising substantially with age. Older women are a vulnerable population at increased risk of developing and dying from breast cancer. However, women aged 75 years and older were excluded from all randomized controlled screening trials, so the best available data regarding screening benefits and risks in this age group are from observational studies and modeling predictions. Benefits of screening in older women are the same as those in younger women: early detection of smaller lower-stage cancers, resulting in less invasive treatment and lower morbidity and mortality. Mammography performs significantly better in older women with higher sensitivity, specificity, cancer detection rate, and positive predictive values, accompanied by lower recall rates and false positives. The overdiagnosis rate is low, with benefits outweighing risks until age 90 years. Although there are conflicting national and international guidelines about whether to continue screening mammography in women beyond age 74 years, clinicians can use shared decision making to help women make decisions about screening and fully engage them in the screening process. For women aged 75 years and older in good health, continuing annual screening mammography will save the most lives. An informed discussion of the benefits and risks of screening mammography in older women needs to include each woman's individual values, overall health status, and comorbidities. This article will review the benefits, risks, and controversies surrounding screening mammography in women 75 years old and older and compare the current recommendations for screening this population from national and international professional organizations. ©RSNA, 2023 Quiz questions for this article are available through the Online Learning Center.
PMID: 37053102
ISSN: 1527-1323
CID: 5464252

Breast Cancer Screening in Survivors of Childhood Cancer

Gao, Yiming; Perez, Carmen A; Chhor, Chloe; Heller, Samantha L
Women who survived childhood cancers or cancers at a young age are at high risk for breast cancer later in life. The accentuated risk is notable among those treated at a young age with a high radiation dose but also extends to survivors treated with therapies other than or in addition to radiation therapy. The predisposing risk factors are complex. Advances in radiation therapy continue to curtail exposure, yet the risk of a second cancer has no dose threshold and a long latency period, and concurrent use of chemotherapy may have an additive effect on long-term risk of cancer. Early screening with annual mammography and MRI is recommended for chest radiation exposure of 10 Gy or greater, beginning 8 years after treatment or at age 25 years, whichever is later. However, there is a lack of recommendations for those at high risk without a history of radiation therapy. Because mortality after breast cancer among survivors is higher than in women with de novo breast cancer, and because there is a higher incidence of a second asynchronous breast cancer in survivors than that in the general population, regular screening is essential and is expected to improve mortality. However, awareness and continuity of care may be lacking in these young patients and is reflected in their poor screening attendance. The transition of care from childhood to adulthood for survivors requires age-targeted and lifelong strategies of education and risk prevention that are needed to improve long-term outcomes for these patients. © RSNA, 2023 See the invited commentary by Chikarmane in this issue. Quiz questions for this article are available through the Online Learning Center.
PMID: 36927127
ISSN: 1527-1323
CID: 5448982